| Entry |
|
|---|
| Name |
Loxapine succinate (USP);
Loxitane (TN) |
|---|
| Product |
|
|---|
| Generic |
LOXAPINE (Actavis Pharma), LOXAPINE (Chartwell RX), LOXAPINE (Coupler LLC), LOXAPINE (Coupler LLC), LOXAPINE (Coupler LLC), LOXAPINE (Elite Laboratories), LOXAPINE (Lannett Company), LOXAPINE (Proficient Rx LP), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK), LOXAPINE (REMEDYREPACK) |
|---|
| Formula |
C18H18ClN3O. C4H6O4
|
|---|
| Exact mass |
445.1404
|
|---|
| Mol weight |
445.89
|
|---|
| Structure |
|
|---|
| Class |
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG01644 CYP2D6 substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG00897): | D02340<US> D00794<US> |
|
|---|
| Efficacy |
Minor tranquilizer, Dopamine D2 receptor antagonist, Serotonin receptor antagonist |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Metabolism |
Enzyme: CYP1A2 [HSA: 1544], CYP3A4 [HSA: 1576], CYP2D6 [HSA: 1565]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
N NERVOUS SYSTEM
N05 PSYCHOLEPTICS
N05A ANTIPSYCHOTICS
N05AH Diazepines, oxazepines, thiazepines and oxepines
N05AH01 Loxapine
D00794 Loxapine succinate (USP) <US>
USP drug classification [BR:br08302]
Antipsychotics
1st Generation/Typical
Loxapine
D00794 Loxapine succinate (USP)
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00897 Loxapine
D00794 Loxapine succinate
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00897 Loxapine
D00794 Loxapine succinate
DG01644 CYP2D6 substrate
DG00897 Loxapine
D00794 Loxapine succinate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00897 Loxapine
D00794 Loxapine succinate
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Dopamine
DRD2
D00794 Loxapine succinate (USP) <US>
Serotonin
HTR2A
D00794 Loxapine succinate (USP) <US>
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00794
Drug groups [BR:br08330]
Neuropsychiatric agent
DG01478 Dopamine antagonist
DG01474 Dopamine D2-receptor antagonist
DG00897 Loxapine
Metabolizing enzyme substrate
DG01892 CYP1A2 substrate
DG00897 Loxapine
DG01644 CYP2D6 substrate
DG00897 Loxapine
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00897 Loxapine
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 31
1 C6a C 38.6351 -18.6142
2 C1b C 37.4213 -19.3202
3 O6a O 39.8548 -19.3202
4 O6a O 38.6351 -17.2194
5 C1b C 36.2133 -18.6200
6 C6a C 35.0053 -19.3260
7 O6a O 33.7914 -18.6259
8 O6a O 35.0053 -20.7208
9 C2y C 28.7700 -17.5000
10 C8y C 27.9300 -16.3800
11 C8y C 28.2800 -15.0500
12 O2x O 29.5400 -14.4900
13 N2x N 30.1700 -17.5000
14 C8y C 30.8000 -15.1200
15 C8y C 31.0800 -16.4500
16 C8x C 27.2300 -14.0700
17 C8x C 25.9000 -14.4900
18 C8y C 25.5500 -15.8200
19 C8x C 26.6000 -16.8000
20 C8x C 32.4100 -16.8700
21 C8x C 33.4600 -15.9600
22 C8x C 33.1800 -14.5600
23 C8x C 31.8500 -14.1400
24 X Cl 24.2200 -16.2400
25 N1y N 28.1400 -18.7600
26 C1x C 26.7400 -18.7600
27 C1x C 26.0400 -19.9500
28 N1y N 26.7400 -21.2100
29 C1x C 28.1400 -21.2100
30 C1x C 28.8400 -19.9500
31 C1a C 26.0400 -22.4000
BOND 33
1 1 2 1
2 1 3 1
3 1 4 2
4 2 5 1
5 5 6 1
6 6 7 1
7 6 8 2
8 11 12 1
9 9 13 2
10 12 14 1
11 10 11 1
12 13 15 1
13 9 10 1
14 14 15 1
15 11 16 2
16 16 17 1
17 17 18 2
18 18 19 1
19 10 19 2
20 15 20 2
21 20 21 1
22 21 22 2
23 22 23 1
24 14 23 2
25 18 24 1
26 9 25 1
27 25 26 1
28 26 27 1
29 27 28 1
30 28 29 1
31 29 30 1
32 25 30 1
33 28 31 1
|
|---|
